Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosimab plus third-generation EGFR-TKIs in slowly or potentially progressing EGFR-mutant advanced NSCLC
ChiCTR2500113360Phase 3Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival (PFS). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500113360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113360.